Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.75 |
| ▸ | CA2 | P00918 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320964 | 0.86 | CA1 (0.71) | CA1CA2ALDH1A1GBA1SIGMAR1 | |
| SCHEMBL7862567 | 0.83 | GBA1 (0.74) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL9229800 | 0.81 | ALDH1A1 (0.67) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL13668160 | 0.81 | CA1 (0.75) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL2934786 | 0.81 | ALDH1A1 (0.67) | CA1CA2ALDH1A1GBA1SIGMAR1 | |
| SCHEMBL28023600 | 0.81 | ALDH1A1 (0.67) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL6790764 | 0.81 | ALDH1A1 (0.67) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL6755663 | 0.81 | CA1 (0.77) | CA1CA2ALDH1A1GBA1GAA | |
| SCHEMBL674105 | 0.81 | ALDH1A1 (0.66) | CA1CA2ALDH1A1GBA1 | |
| SCHEMBL6595288 | 0.81 | MEN1 (0.64) | CA1CA2ALDH1A1GBA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7642256-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-01-05 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566735-B2 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | HARRISON STEPHEN | 2009-05-07 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| WO-2007107539-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118280-A1 | Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | CA1 835/4885CA2 1707/4885ALDH1A1 1395/4885 |
| US-20080045532-A1 | Compounds which potentiate AMPA receptor and uses thereof in medicine | GRIN1, GRM2, GRM1 | CA1 835/4885CA2 1707/4885ALDH1A1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.